Avutometinib/Defactinib (Avmapki Fakzynja Co-Pack) FDA Approved
Avmapki Fakzynja Co-Pack, a co-packaged oral combination of avutometinib capsules and defactinib tablets, received accelerated approval from the U.S. FDA on May 8, 2025 for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have undergone at least one prior systemic therapy